HGSI Gets Slightly Increased Buyout Bid, Accepts GSK Offer Of $3.6 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
After three months of battling, with lupus drug Benlysta still struggling, Human Genome Sciences accepted a modestly increased sales offer from partner GlaxoSmithKline.